Literature DB >> 806708

The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.

H Hisazumi, T Uchibayashi, K Naito, T Misaki, K Miyazaki.   

Abstract

The prevention of recurrences of bladder cancer was attemped in 48 patients by means of the combined intravesical instillation of thio-tepa and urokinase and in 28 patients through the instillation of thio-tepa alone. The recurrence rates of both therapies for the postoperative 18 months were 7.9 and 32.6 per cent, respectively, indicating a significant drop in the recurrence rate in the group subjected to the combined therapy. No significant difference was found between the 2 instillation groups in terms of the blood transmission of 32-P thio-tepa. Serious leukopenia was found in 2 of the 48 patients receiving the combined instillation therapy but we concluded that this was not attributable to the use of urokinase.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 806708     DOI: 10.1016/s0022-5347(17)67038-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Local application of THIO-TEPA in the prevention of recurrent papillary carcinoma of the bladder.

Authors:  M Csellár; A Csontai
Journal:  Int Urol Nephrol       Date:  1979       Impact factor: 2.370

2.  ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80.

Authors:  J R Masters; B J McDermott; W E Jenkins; E Fenwick; P J Shah; A R Mundy; P M Loadman; M C Bibby
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Anticancer drug sensitivity in vitro in the bladder cancer cell line, KK-47 and prophylactic use of carbazilquinone and urokinase in bladder cancer.

Authors:  H Hisazumi; T Uchibayashi; M Katoh; T Kobayashi; K Nakajima; K Naitoh; T Misaki; K Kuroda
Journal:  Urol Res       Date:  1981
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.